Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Company Overview

Corporate Directory

Corporate Governance

Board

Team

Clinical Advisers

Values

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

Amplia has today announced that it has received a Research and Development Tax Incentive Refund of$3,177,718 for the 2023/2024 financial year.

The refund relates to expenditure incurred in research and development associated with the Company’s FAK inhibitors, narmafotinib (AMP945) and AMP886, and are primarily related to the Company’s ongoing Phase 1b/2a clinical trial of narmafotinib in advanced pancreatic cancer patients.

The Australian Government's Research and Development Tax Incentive is a program to encourage businesses to undertake research and development (R&D) activities and provides eligible companies with cash refunds for 43.5-48.5% of eligible expenditure on research and development activities.

Click link below to read the full ASX Release.

Amplia receives R&D Tax Rebate